Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in Italy

Abstract

Mogamulizumab is a humanized monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity that targets chemokine receptor type. Several clinical trials and real-life experiences confirmed the efficacy and safety profiles of mogamulizumab as second-line therapy and beyond, and the biochemical- and dermatology-specific quality of life and physical functioning, with high treatment satisfaction. Systemic drugs are usually used in patients with resistant or advanced forms of cutaneous T-cell lymphomas (especially mycosis fungoides) or with Sézary Syndrome, while early-stage mycosis fungoides can be managed at least initially with local treatments. The most recent Guidelines confirm this approach, but recommend also an anticipated use (starting from the second line) of new therapeutic agents in advanced skin lymphomas. In this report, we discuss eight cases of patients with mycosis fungoides or Sézary Syndrome successfully managed with an anticipated use of mogamulizumab in real-life clinical practice in Italy.